An Official Journal of The Society for Healthcare Epidemiology of America


PUBLISHED FOR THE SOCIETY BY SLACK INCORPORATED

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL

Dale N. Gerding, MD	253
DRIGINAL ARTICLES	
Practices to Improve Antimicrobial Use at 47 US Hospitals: The Status of the 1997 SHEA/IDSA Position Paper Recommendations	
RACHEL M. LAWTON, MPH; SCOTT K. FRIDKIN, MD; ROBERT P. GAYNES, MD; JOHN E. MCGOWAN, JR, MD; AND THE INTENSIVE CARE ANTIMICROBIAL RESISTANCE EPIDEMIOLOGY (ICARE) HOSPITALS	25
Nosocomial Infections in Pediatric Patients:	
A European, Multicenter Prospective Study Josette Raymond, MD; Yannick Aujard, MD; the European Study Group	26
Comparison of Higher-Dose Intradermal Hepatitis B Vaccination to	
Standard Intramuscular Vaccination of Healthcare Workers	
Elizabeth A. Henderson, PhD; Thomas J. Louie, MD, FRCPC; Karam Ramotar, PhD; Donna Ledgerwood, RN, BN; Karen Myrthu Hope, MSc; Agnes Kennedy, RN, BN	26
CONCISE COMMUNICATIONS	
Evidence of Delays in Transferring Patients With Methicillin-Resistant	
Staphylococcus aureus or Vancomycin-Resistant Enterococcus to Long-Term–Care Facilities	
ELIZABETH A. BRYCE, MD, FRCPC; SHELLEY M. TIFFIN, ART, BMLSC; JUDITH L. ISAAC-RENTON, MD, FRCPC;	
CHARLES J. WRIGHT, MD, FRCPC	27
The Incidence and Risk Factors of Ventilator-Associated Pneumonia	
in a Riyadh Hospital Ziad A. Memish, MD, CIC; Gwen Cunningham, RN, CIC; Gbolahan A. Oni, PhD; W. Djazmati, MD	27
SSUES IN SURGERY	
O₂ in Y2K: Not An Airtight Case James T. Lee, MD, PhD	27
TATISTICS FOR HOSPITAL EPIDEMIOLOGY	
Diagnostic Tests: Distinguishing Good Tests From Bad and Even Ugly Ones	
Diagnosuu resis: Disunguishing uuuu resis rium dau anu even upiv unes	

Continued inside.



Bactroban Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.

Single-use tube (actual size)

In a hospital study, Bactroban Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.



Excellent safety profile

The most frequently reported adverse events were headache (9%), rhinitis (6%), respiratory disorder (including upper respiratory tract congestion) (5%), pharyngitis (4%) and taste perversion (3%). Safety in children under 12 years of age has not been established in controlled clinical trials.

Contraindications ... Do not use Bactroban Nasal in patients with known hypersensitivity to any of the constituents of the product.

Please see brief summary of prescribing information on adjacent page.

References: 1. Bactroban® Nasal prescribing information, 1995. 2. Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.





BN2760 ©SmithKline Beecham, 1999 Philadelphia, PA



2% ointment for intranasal use

BACTROBAN® NASAL (mupirocin calcium ointment), 2% Brief summary. For complete prescribing information, see package insert.

INDICATIONS AND USAGE

NDICATIONS AND USAGE Bactroban Nasal is indicated for eradication of nasal coloniza-tion with methicillin-resistant Staphylococcus aureus in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

- NOTE: Note: 1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infec-tion in any patient population.
- tion in any patient population. Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after com-pletion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/ patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-thera-py with 85% to 100% recolonization within 4 weeks. **NTRAINDICATIONS** (3)

by with box to the second and the se WARNINGS

WARNINGS AVOID CONTACT WITH THE EYES. Application of Bactroban Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from Bactroban Nasal, usage should be discontinued.

PRECAUTIONS

PRECAUTIONS General: As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See DOSAGE AND ADMINISTRATION in complete prescribing information.)

complete prescribing information.) Information for Patients: Patients should: apply approxi-mately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nos-tril, avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gen-ly massage after application to spread the ointment through-out the inside of the nostrils; and discontinue using Bactroban Nasal and call a health care practitioner if sensitization or severe local irritation occurs. severe local irritation occurs.

Drug Interactions: The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

2% concurrently with any other intranasal products. Carcinogenesis, Mutagenesis, Impairment of Fertility: Long-term studies in animals to evaluate carcinogenic poten-tial of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium in vitro and in vivo did not indicate a poten-tial for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, Salmo-nella reversion test (Ames), Escherichia coli mutation assay, metaphase analysis of human lymphocytes, mouse lym-phoma assay, and bone marrow micronuclei assay in mice. Aeproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of impaired fertility from mupirocin sodium. Preenancy: Teratogenic Effects, Pregnency Category B.

fertility from mupirocin sodium. **Pregnancy: Teratogenic Effects. Pregnancy Category B.** Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of harm to the fetus due to mupiro-cin. There are, however, no adequate and well-controlled stud-ies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. **Nursing Mothers:** It is ont known whether this drug is excet-

Nursing Mothers: It is not known whether this drug is excret-ed in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

Pediatric Use: Safety in children under the age of 12 years has not been established. (See CLINICAL PHARMACOLOGY in complete prescribing information.)

ADVERSE REACTIONS


ADVERSE REACTIONS Clinical Trials: In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received Bactroban Nasal oint-ment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treat-ed with Bactroban Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respira-tory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; taste perversion, 1% following events thought possibly drug-related were

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nau-sea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

OVERDOSAGE

Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.


Manufactured by DPT Laboratories, San Antonio, TX 78215 Distributed by SmithKline Beecham Pharmaceuticals, Philadelphia, PA 19101 BRS-BN:L3



ACK 6900 Grove Road, Thorofare, NJ 08086

HATS OFF TO FIRST CLASS SERVICE

At SLACK Incorporated we believe our subscribers are first class



EDITORIAL OFFICES Vanderbilt University School of Medicine A-1131 Medical Center North Nashville, TN 37232-2637 (615) 343-1095; (615) 343-1882 (FAX) Email: iche@mcmail.vanderbilt.edu EDITOR Michael D. Decker, MD, MPH MANAGING EDITOR Susan Cantrell STATISTICAL EDITOR Beverly G. Mellen, PhD SENIOR ASSOCIATE EDITORS C. Glen Mayhall, MD Gina Pugliese, RN, MS William Schaffner, MD ASSOCIATE EDITORS Donald A. Goldmann, MD Didier Pittet, MD, MS Andreas Widmer, MD, MS SECTION EDITORS **Beyond Infection Control:** The New Hospital Epidemiology Bryan P. Simmons, MD Stephen B. Kritchevsky, PhD Memphis, Tennessee Wing Hong Seto, MD Hong Kong **Disinfection and Sterilization** William A. Rutala, PhD, MPH Chapel Hill, North Carolina **Emerging Infectious Diseases** Larry J. Strausbaugh, MD Portland, Oregon Robert W. Pinner, MD Atlanta, Georgia From the Laboratory Marcus Zervos, MD Royal Oak, Michigan Fred C. Tenover, PhD Atlanta, Georgia Information Management John A. Sellick, DO Buffalo, New York The International Perspective Mary D. Nettleman, MD, MS Richmond, Virginia **Issues in Surgery** James T. Lee, MD, PhD St. Paul, Minnesota Medical News Gina Pugliese, RN, MS Chicago, Illinois Martin S. Favero, PhD Irvine, California Practical Healthcare Epidemiology Loreen A. Herwaldt, MD Iowa City, Iowa SHEA News Andreas Voss, MD, PhD Nijmegen, The Netherlands Statistics for Hospital Epidemiology David Birnbaum, PhD, MPH Sidney, British Columbia, Canada **Topics in Long-Term Care** Philip W. Smith, MD Omaha, Nebraska **Topics in Occupational Medicine** David Weber, MD, MPH Chapel Hill, North Carolina

Vice President/Group Publisher Richard N. Roash Publisher John C. Carter Editorial Director Jennifer Kilpatrick Production Editor Shirley P. Strunk, ELS Assistant Editor Eileen C. Anderer

4667 Published online by Cambi

idg

https://doi.org

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL ADVISORY BOARD

Jacques F. Acar, MD J. Wesley Alexander, MD Paul Arnow, MD Graham A.J. Ayliffe, MD Neil L. Barg, MD Elizabeth Ann Bolyard, RN, MPH, CIC John M. Boyce, MD Professor Dr. Ilja Braveny Christian Brun-Buisson, MD Charles Bryan, MD Donald E. Craven, MD Sue Crow, MSN, RN, CIC Franz Daschner, MD Leigh G. Donowitz, MD Charles E. Edmiston, Jr., PhD Theodore C. Eickhoff, MD Bruce Farber, MD Victoria J. Fraser, MD Peter C. Fuchs, MD, PhD Richard A. Garibaldi, MD Robert Gaynes, MD Velvl Greene, PhD, MPH David W. Gregory, MD David K. Henderson, MD Peter N.R. Heseltine, MD Karen Hoffmann, RN, CIC, MS Marguerite McMillan Jackson, RN, PhD Janine Jagger, MPH, PhD William R. Jarvis, MD Douglas S. Kernodle, MD Robert H. Latham, MD Lewis B. Lefkowitz, MD Hsieh-Shong Leu, MD, MSc Jack Levy, MD Victor Lorian, MD Dennis G. Maki, MD William J. Martone, MD Allison McGeer, MD John E. McGowan, Jr., MD Jonathan L. Meakins, MD, DSc Robert R. Muder, MD Joseph M. Mylotte, MD, CIC Lindsay Nicolle, MD Juhani Ojajärvi, MD Michael T. Osterholm, PhD, MPH Jan Evans Patterson, MD Sindy M. Paul, MD Michael A. Pfaller, MD Samuel Ponce de Leon, MD, MSc Isaam Raad, MD Manfred L. Rotter, MD, DipBact Theodore Sacks, MD William E. Scheckler, MD Kent Sepkowitz, MD Denis Spelman, MD Michael L. Tapper, MD Clyde Thornsberry, PhD Professor Leonid P. Titov Timothy R. Townsend, MD Antoni Trilla, MD, PhD Professor Wang Shu-Qun J. John Weems, Jr., MD Robert A. Weinstein, MD Professor Dr. W. Weuffen Sergio B. Wey, MD Rebecca Wurtz, MD

Paris, France Cincinnati, Ohio Chicago, Illinois Birmingham, United Kingdom Yakima, Washington Atlanta, Georgia Providence, Rhode Island Munich, Germany Creteil, France Columbia, South Carolina Boston, Massachusetts Shreveport, Louisiana Freiburg, Germany Charlottesville, Virginia Milwaukee, Wisconsin Denver, Colorado Manhasset, New¥ork St. Louis, Missouri Black Butte, Oregon Farmington, Connecticut Atlanta, Georgia Beer Sheva, Israel Nashville, Tennessee Bethesda, Maryland Los Angeles, California Chapel Hill, North Carolina San Diego, California Charlottesville, Virginia Atlanta, Georgia Nashville, Tennessee Nashville, Tennessee Nashville, Tennessee Taipei, Taiwan Brussels, Belgium Bronx, New York Madison, Wisconsin Bethesda, Maryland Toronto, Ontario, Canada Atlanta, Georgia Montreal, Quebec, Canada Pittsburgh, Pennsylvania Buffalo, New York Winnepeg, Manitoba, Canada Helsinki, Finland Minneapolis, Minnesota San Antonio, Texas Trenton, New Jersey Iowa City, Iowa Mexico City, Mexico Houston, Texas Vienna, Austria Jerusalem, Israel Madison, Wisconsin New York City, New York Prahran Victoria, Australia New York, New York Brentwood, Tennessee Minsk, Republic of Belarus Millwood, Virginia Barcelona, Spain Beijing, People's Republic of China Greenville, South Carolina Chicago, Illinois Greifswald, Germany São Paulo, Brazil Evanston, Illinois

SLACK Incorporated 6900 Grove Road Thorofare, New Jersey 08086 (856) 848-1000 **Editorial Assistant** Aileen Schneider Circulation Manager Lester J. Robeson, CCCP **Production Director** Christine Malin **Production Coordinator** Ioanne Patterson Publishing Director/ Advertising Wayne McCourt dge University Press

Pharmaceutical Group Sales Director Michael LoPresti Advertising Sales Representative Tina Panna Advertising Sales Coordinator Jill Campise Classified/Recruitment Sales Manager Kathy Huntley Classified/Recruitment Sales Representative Katie Ford

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY**

C Ο Ν Τ Ε Ν Τ S

Continued from cover

LETTERS TO THE EDITOR

Survival of Acinetobacter on Three Clinically Related Inanimate Surfaces CAROL WEBSTER, PHD; KEVIN J. TOWNER, PHD; HILARY HUMPHREYS, MD	246
Creutzfeldt-Jakob Disease: Management of Accidental Contamination of Neurosurgical Instruments, Pathology Equipment, and Solutions ELIZABETH ANN BRYCE, MD; KATERINA DOROVONI-ZIS, MD; DIANNE TRUDEAU; MARGARET SINCLAIR; FRED J. ROBERTS, MD	247
Disinfection of Hospital Laundry Using Ozone: Microbiological Evaluation Claudia Catelani Cardoso, DVM; João E. Fiorini, PhD; Luciano R. Ferriera, PhD; José W.B. Gurjão, ChemEng; Luiz A. Amaral, PhD	248
Impact of Nosocomial Infections on Outcome: Myths and Evidence (with reply) ALEJANDRO E. MACÍAS, MD; JORDI RELLO, MD, PHD	248
Reasons That Healthcare Workers Decline Influenza Vaccination in a New Zealand Hospital Environment CHRIS WALLS, MB, CHB, AFOM	249
Risk Factors for Nosocomial Infection in a High-Risk Nursery Rahaman O. Suara, MD; Michal Young, MD; Inez Reeves, MD	250
Once MRSA, Always MRSA? Setting up a Hospital Preadmission Questionnaire Johan H.T. Wagenvoort, MD, PhD; Hub M.J. Toenbreker; Theo J. Werink; Hein H.G. Berendsen	251
OOK REVIEWS Hospital Infections, 4th ed (Bennett JV, Brachman PS) KEITH F. WOELTJE, MD, PHD	285
Hospital Epidemiology and Infection Control, 2nd ed (Mayhall CG) ROBERT H. LATHAM, MD	285
Antimicrobial Therapy and Vaccines (Yu VL, Merigan TC Jr, Barriere SL) MICHAEL T. BRADY, MD	286
EDICAL NEWS Gina Pugliese, RN, MS; Martin S. Favero, PhD	287
HEA NEWS Andreas Voss, MD, PhD	296
To view abstracts of these articles,	

To view abstracts of these articles, visit us on the Internet at http://www.slackinc.com/general/iche

The publication of advertising in the Journal does not constitute any guarantee or endorsement by The Society for Healthcare Epidemiology of America or Slack Incorporated of the advertised product or service or of claims made by the advertiser. The publication of articles and other editorial material in the Journal does not necessarily represent the policy recommendations or endorsement by the Society.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (856) 848-1000.

SHEA: 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 856-423-0087; fax, 856-423-3420; e-mail address, sheahq@talley.com.

COPYRIGHT 2000 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$110.00; Two years\$148.00; Three years\$181.00; Institutional: One year-\$133.00; Two years\$183.00; Three years\$233.00. Fellows: \$55.00 per year with proof of training status. Canada: \$20.00 additional each year plan for Canadian Goods & Services tax; Overseas surface, \$150.00 each year; Overseas air mail, \$195.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

INSTRUCTIONS TO AUTHORS: Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (http://www.slackinc.com/general/iche/ichehome.htm). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

REPRINTS: All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (856) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNdex Top 100.

All The Facts For Your Immunization Program





Both textbooks are an official publication of The Society of Healthcare Epidemiology (SHEA).

Immunizing Healthcare Workers: A Practical Approach

Edited by Gregory A. Poland, MD; William Schaffner, MD; Gina Pugliese, RN, MS 300 pp, Hard Cover, 2000, ISBN 1-55642-450-7, Order # 14507, \$109.00

Immunizing Healthcare Workers: A Practical Approach is the first complete resource for dealing with the immunization of healthcare workers. You can find all of the latest information on successfully and safely implementing or updating your immunization program in this landmark book.

Inside you will find that for each of the vaccine-preventable diseases among workers, there is a discussion of disease risks in the healthcare setting, vaccine recommendations, special administration strategies, safety issues, discussion of unresolved issues, and answers to commonly asked questions. There are also case studies of sample programs in specific settings. This phenomenal book contains the latest re mendations from the US Public Health & Advisory Committees, Healthcare Infection (C Practices Advisory Committee (HICPAC), an Advisory Committee on Immunization Pra (ACIP).

Read how the experts overcame obstacles setting up immunization programs in their heal settings. With over 45 contributors to 32 cha **Immunizing Healthcare Workers:** A Pra **Approach** is an essential source for the information necessary to implement an effi immunization program.

Some Case Study Topics:

- Immunizing Providers and Staff in Physicians' Offices
- Vaccination of Healthcare Workers in Long-Term Care Facilities for the Elderly
- Immunization of Affiliating Students and Contract Home Healthcare Workers
- Immunization Strategies for Home Healthcare Personnel

- Immunization of Workers with Altered Host Defenses
- Vaccinating Unimmunized and Partially Immunized Workers
- Assessing Immunity and Exposures: Using a Computerized Surveillance System
- Managing Information in an Immunization Program
- The Internet: A Quick Guide to Vaccine & Immunization Inform

ORDER FORM

Please send me _____ copies of Immunizing Healthcare Workers: A Practical Approach Order# 14507) at \$109.00 each.

Please send me _____ copies of **A Practical Handbook for Hospital Epidemiologists** Order # 13020) at **\$65.00** each.

NJ resident	ts add 6% sales tax Handling Total	\$_4.50			
lame:		in the Constant of the State of		and the set of a set of the set o	
ddress:				(all all all all all all all all all all	and the second second
ity:	the day we are shield	and many head	State:	Zip:	And the second second second
hone:			Fax:		and the second second
-mail:	deckerplent Konst	of beforing at start	de dimensione and and	terrent distriction terrent	og so ingradui us pool
Check encl	osed (Payable to SI	LACK Incorpo	orated)		
harge my:	- 7112 @ 4588.	U VISA	MasterCard		
ccount #:	States and and and	and the second second	Cana Para and Para and Para	the life of the life of the	WE ARE ANTER PROPERTY
https://doi.or xp. date:	g/10.1017/S0195941700 Sigr	054667 Publishe	d online by Cambridge Uni	versity Press	terrent and the second s
	ect to change Shippin				CODE: 14448


Also Available

A Practical Handbook for Hospital Epidemiolo Edited by: Loreen A. Herwaldt, MD and co-edited by Michael D. Decker, MD, MPH 448 pp, Soft Cover, 1998, ISBN 1-55642-302-0, Order # 13020, \$65.00

A Practical Handbook for Hospital Epidemiologists most complete source for practical advice on hospital epi ogy. It is intended to be a pragmatic guide that will ass beginning and experienced practitioners in establishing ar ating a successful hospital epidemiology program. The book will supplement the various scientific references available for this field and will help hospital epidemi improve their practices.

Mail order form to: SLACK Incorporated, Professional Book Divisio 6900 Grove Road, Thorofare, NJ 08086-944/

Call: (800) 257-8290 or (856) 848-1000 Fax: (856) 853-5991 E-mail: orders@slackinc.com World Wide Web Site: http://www.slackinc.c



When your career's at Tenet, you don't have co-workers. You have teammates. You have partners. You have friends. People who are there for you. To share your joy. And your sadness. You might call that a little thing. But to me, it made all the difference in the world.

A member of Tenet HealthSystem, Piedmont Healthcare System is a fully accredited, full-service healthcare facility located in Rock Hill, South Carolina, just 20 miles south of Charlotte, North Carolina. We're big enough to offer you plenty of opportunity, yet small enough to ensure you won't be just another name on an ID or another face in the crowd.

Infection Control Coordinator

This position is responsible for coordinating infection control surveillance twoughout the hospital. The qualified candidate should possess a South Carolina RN license, two years experience in a hospital nursing environment as well as infection control experience. Bachelor's degree in Nursing and cartification in Infection Control are preferred.

Please mail or fax your resume to: Piedmont Healthcare System, Human Resources Dept., 222 S. Herlong Avenue, Rock Hill, SC 29732. Phone (803) 329-6855. Fax (803) 329-6798. JOBLINE (803) 366-1400. EOE

www.teamtenet.com

Piedmont Healthcare System

All the difference in the world.

Experience Outdoor Alaska in Minutes.

Located in Anchorage, Providence Alaska Medical Center offers you the unique opportunity to work just minutes from endless outdoor recreation and enjoy wildlife and adventures in everyday places. If you want to discover year-round adventures and great career potential, consider joining Providence Alaska.

Program Coordinator, Epidemiology Services

Position supervises, coordinates and directs all epidemiological activities including infection control procedures and programs. Bachelors degree in Nursing or related health care field. Minimum of two years experience in Infection Control from a comparable facility. Knowledge of the principles of epidemiology is preferred.

Please send your resume to: Providence Health System Alaska, Human Resources, PO Box 196990, 701 East Tudor, Suite 135, Anchorage, AK 99519; PHONE: (800) 478-9940; FAX: (907) 565 6499; Email: bmcneil@provak.org EOE. Drug screening required

For more information on Alaska, visit www.state.ak.us



Providence Health System Alaska

W W W . P R O V I D E N C E . O R G / A L A S K A

Mothers. Spouses. (maybe) Medical Matrix.

caring difference vou can

What do they have in common? You place your trust in them. When searching the Internet for credible medical information, you need a resource you can trust. *The Lancet* quotes that "Medical Matrix is the most comprehensive compendium of reliable medical information on the Internet."



mp://www.medindmix.org

The largest, peer-reviewed directory to the medical Internet.

Free registration.